Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 1509 of 5804
-
Radioactive drug lutathera takes on brain cancer in early trial
Disease control OngoingA Dose Finding Study of \[177Lu\]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination with Standard of Care and in Recurrent Glioblastoma as a Single Agent
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Brain pacemaker tweak could help stroke and tremor patients speak and swallow better
Symptom relief Recruiting nowThis study aims to recruit patients already implanted with Deep Brain Stimulation (DBS) for movement disorders to complete tasks assessing parameters of motor output, speech, and swallowing functions, both with and without stimulation. DBS parameters would be adjusted prior to mo…
Phase: NA • Sponsor: Jorge Gonzalez-Martinez • Aim: Symptom relief
Last updated Jun 27, 2026 08:04 UTC
-
Battle of the devices: which tool best mends a broken spleen?
Disease control CompletedOur aim is to conduct a multi-center, Bayesian, randomized clinical trial to evaluate the primary technical success of coils and vascular plugs for proximal splenic artery embolization in the setting of high-grade splenic trauma. The investigator has previously demonstrated the f…
Phase: NA • Sponsor: Andrew J. Gunn • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New PET scan could spot hidden diseases early
Diagnosis Recruiting nowThis prospective, single-center study investigates the biodistribution, dosimetry, safety, diagnostic performance of Al18F-NOTA-FAPI PET imaging in patients with malignant tumor,cardiovascular or immune disease. And evaluates the potential of Al18F-NOTA-FAPI PET imaging in Clinic…
Phase: PHASE1, PHASE2 • Sponsor: Peking Union Medical College Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 09:03 UTC
-
Can a digital hub keep mentally ill patients healthy at home?
Disease control OngoingIndividuals suffering from Serious Mental Illnesses (SMI) are at risk for serious adverse health and social outcomes compared to the general population due to a high prevalence of chronic physical health disorders such as cardiovascular disease, hypertension, and Type II Diabetes…
Phase: NA • Sponsor: University of Maryland, Baltimore • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Could an 8-Day heart patch prevent your next stroke?
Diagnosis CompletedThe purpose of this study is to evaluate the benefits in the atrial fibrillation detection rate of the continuous ECG monitoring group for more than 8 days by contrasting with one-day ECG monitoring using MEMO Patch PLUS in 1000 patients with atrial fibrillation-related symptoms …
Phase: NA • Sponsor: Yonsei University • Aim: Diagnosis
Last updated Jul 03, 2026 00:00 UTC
-
New shot shows promise for stubborn high fats in blood
Disease control CompletedThe purpose of the study was to evaluate the effect of olezarsen on percent change in fasting triglyceride (TG) levels compared to placebo at Months 6 and 12 and the proportion of participants who achieve different thresholds in fasting TG. Other objectives were to evaluate the e…
Phase: PHASE2 • Sponsor: Ionis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Could an asthma drug tame COPD Flare-Ups? new study investigates
Disease control CompletedThe investigators aim to recruit 32 people with COPD who have frequent exacerbations and high eosinophil counts which indicates "asthmatic type" inflammation and treat them for a year with mepolizumab. This is a licenced medication for asthma. Mepolizumab is a monoclonal antibody…
Phase: PHASE3 • Sponsor: Sheffield Teaching Hospitals NHS Foundation Trust • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Could a light cap ease autism symptoms in young children?
Symptom relief CompletedThe hypothesis of the study is that photobiomodulation reduces symptoms of autism. Participants will be children between the ages of 2 and 7, who have been diagnosed with moderate to severe autism. Transcranial photobiomodulation will be administered to the children in the experi…
Phase: NA • Sponsor: JelikaLite LLC • Aim: Symptom relief
Last updated Jul 09, 2026 00:00 UTC
-
New drug targets Hard-to-Treat blood cancers in chinese trial
Disease control Recruiting nowThis study aims to explore the recommended phase 2 dose and evaluate the safety, tolerability and preliminary antitumor activity of BGB-16673 monotherapy at the recommended Phase 2 dose for the selected B-cell malignancy expansion cohorts
Phase: PHASE1, PHASE2 • Sponsor: BeiGene • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
Off-the-Shelf immune cells take on Hard-to-Treat lymphomas
Disease control Recruiting nowThis phase I trial is to find out the best dose, possible benefits and/or side effects of third-party natural killer cells in combination with mogamulizumab in treating patients with cutaneous T-cell lymphoma or adult T-cell leukemia/lymphoma that has come back (relapsed) or does…
Phase: PHASE1 • Sponsor: John Reneau • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Can community workshops and couple counseling curb HIV in cape town?
Prevention CompletedThis study addresses HIV prevention and treatment for young couples living in Cape Town, South Africa, through a comprehensive biobehavioral multilevel approach-the Couples Health CoOp Plus (CHC+). Through a cluster randomized trial with a modified factorial design, 24 Cape Town…
Phase: NA • Sponsor: RTI International • Aim: Prevention
Last updated Jun 27, 2026 07:59 UTC
-
Stroke device could revolutionize heart attack treatment
Disease control CompletedHeart attacks are caused by the sudden formation of a clot inside a diseased coronary artery which reduces blood flow beyond the blockage site. During conventional treatment of the blockage with what is known as a stent; a stainless steel tub that keeps the artery open, the clot …
Phase: NA • Sponsor: Oxford University Hospitals NHS Trust • Aim: Disease control
Last updated Jun 26, 2026 13:36 UTC
-
Could a Neck-Strengthening device speed up concussion recovery?
Disease control CompletedConcussions occur most frequently in adolescents and often result in significant disruption to daily living for prolonged periods of time. Concussions are an epidemic, with the incidence rates for sports related concussions (SRC) in adolescents up to 0.47 per 1000 athlete exposur…
Phase: NA • Sponsor: Western University, Canada • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Can drug combo before surgery boost ovarian cancer outcomes?
Disease control Recruiting nowThis is a multi-center, prospective, open-label, phase II trial. Patients with suspected advanced ovarian cancer planned to undergo diagnostic laparoscopy for histologic confirmation and evaluation of disease spread will be registered into the trial after providing a 1st written …
Phase: PHASE2 • Sponsor: AGO Research GmbH • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Could a lung fibrosis drug stop nosebleeds in HHT?
Symptom relief Recruiting nowPatients affected by hereditary hemorrhagic telangiectasia (HHT) very often suffer from recurrent nosebleeds called epistaxis. There is no treatment currently available to reduce the frequency or severity of epistaxis. This research project will examine the effect of nintedanib,…
Phase: PHASE2 • Sponsor: Dr. Romain Lazor • Aim: Symptom relief
Last updated Jun 27, 2026 11:01 UTC
-
Experimental drug combo aims to tame bone marrow cancer
Disease control Recruiting nowThe purpose of the study is to identify the recommended Part 2 dose (R2PD) of imetelstat sodium in combination with ruxolitinib in participants with myelofibrosis (MF) in Part 1, and to evaluate the safety and preliminary clinical activity of the R2PD of imetelstat sodium in comb…
Phase: PHASE1 • Sponsor: Geron Corporation • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Experimental antibody combo shows promise against tough cancers
Disease control CompletedThis is a phase I/IIa, two-part, open-label study to characterize the safety, tolerability, pharmacodynamics, and antitumor activity of ICT01 in combination with LDSC IL-2 in patients with advanced-stage solid tumors. Part 1 will be a dose escalation of IV ICT01 administered on …
Phase: PHASE1, PHASE2 • Sponsor: ImCheck Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
MS drug ocrelizumab tested for Long-Term safety in 1,300 patients
Disease control OngoingThis is a Phase IIIb, single-arm, multicenter, OLE study. Participants receiving ocrelizumab as an investigational medicinal product (IMP) in a Roche sponsored Parent study who continue to receive ocrelizumab or are in safety follow-up at the time of the closure of their respecti…
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New drug combo tested for advanced kidney cancer shows promise but study halted early
Disease control TerminatedThis phase II trial investigates the effect of sitravatinib and nivolumab in treating patients with clear cell renal cell cancer that has spread to other places in the body (metastatic/advanced). Sitravatinib may stop the growth of tumor cells by blocking some of the enzymes need…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 11:04 UTC